Hemophagocytic Lymphohistiocytosis (HLH) and Macrophage Activation Syndrome (MAS): Understanding Cytokine Storm Syndromes

Introduction

Hemophagocytic Lymphohistiocytosis (HLH) and Macrophage Activation Syndrome (MAS) are severe hyperinflammatory conditions that fall under the broader category of Cytokine Storm Syndromes (CSS) or Hyperinflammatory Syndromes. These syndromes are characterized by an uncontrolled and excessive immune response, leading to the overproduction of inflammatory cytokines—a phenomenon often referred to as a "cytokine storm." The resulting systemic inflammation can cause multi-organ dysfunction and is life-threatening if not promptly recognized and treated. Understanding the pathophysiology, diagnostic criteria, and management of HLH and MAS is crucial for healthcare providers, especially in acute care settings.

Pathophysiology

Both HLH and MAS are driven by an aberrant immune response, where the activation of macrophages and T-lymphocytes becomes uncontrolled. This leads to an overproduction of pro-inflammatory cytokines such as IFN-γ, IL-6, IL-1, and TNF-α. The excessive activation of these immune cells results in widespread inflammation and tissue damage.

• HLH involves a more systemic immune dysregulation, which can be either genetic (familial HLH) or acquired (secondary HLH), often triggered by infections, malignancies, or autoimmune diseases.

• MAS, on the other hand, is primarily associated with rheumatic diseases, particularly systemic juvenile idiopathic arthritis (sJIA) and systemic lupus erythematosus (SLE).

The uncontrolled immune response in both conditions leads to the activation of macrophages that engulf blood cells, a process known as hemophagocytosis, contributing to cytopenias and organ dysfunction.

---

Clinical Presentation

HLH and MAS share many clinical features due to their common pathophysiological roots. However, there are distinct differences in their clinical contexts.

Hemophagocytic Lymphohistiocytosis (HLH)

• Pathophysiology: HLH is characterized by an uncontrolled and ineffective immune response, where there is excessive activation of lymphocytes and macrophages. This hyperactivation results in:

  • Cytokine Storm: Overproduction of inflammatory cytokines such as IFN-γ, IL-6, IL-1, TNF-α, and others, leading to severe systemic inflammation.

  • Hemophagocytosis: Activated macrophages engulf erythrocytes, leukocytes, platelets, and their precursors in the bone marrow and other tissues.

  • Organ Dysfunction: Due to the excessive inflammation and immune cell infiltration, multiple organs can be affected, including the liver, spleen, bone marrow, and central nervous system.

  Clinical Presentation:

  • Prolonged high fever

  • Splenomegaly (enlarged spleen)

  • Hepatomegaly (enlarged liver)

  • Lymphadenopathy (swollen lymph nodes)

  • Neurological symptoms (seizures, altered mental status)

  • Rash

  Laboratory Findings:

  • Hyperferritinemia: Elevated ferritin levels (>500 ng/mL, often >10,000 ng/mL)

  • Cytopenias: Affects at least two of three cell lines (anemia, thrombocytopenia, neutropenia)

  • Hypertriglyceridemia and/or hypofibrinogenemia: Elevated triglycerides (>265 mg/dL) or low fibrinogen (<1.5 g/L)

  • Elevated soluble IL-2 receptor (sCD25): Indicates T-cell activation

  • Hemophagocytosis: Observed in bone marrow, spleen, or lymph nodes

  Diagnostic Criteria (HLH-2004): Five out of the following eight criteria need to be met:

  1. Fever

  2. Splenomegaly

  3. Cytopenias (affecting ≥2 of 3 lineages in peripheral blood)

  4. Hypertriglyceridemia (≥265 mg/dL) and/or hypofibrinogenemia (≤1.5 g/L)

  5. Hemophagocytosis in bone marrow, spleen, lymph nodes, or liver

  6. Low or absent NK cell activity

  7. Ferritin ≥500 ng/mL

  8. Elevated soluble CD25 (sIL-2 receptor alpha) ≥2400 U/mL

  Management:

  • Immunosuppressive Therapy: HLH-94 or HLH-2004 protocols (etoposide, dexamethasone, cyclosporine)

  • Biologic Agents: Anakinra (IL-1 receptor antagonist), ruxolitinib (JAK inhibitor)

  • Hematopoietic Stem Cell Transplantation: For familial/genetic cases
    

Macrophage Activation Syndrome (MAS)

• Pathophysiology: MAS is a severe, potentially life-threatening complication of rheumatic diseases, particularly systemic juvenile idiopathic arthritis (sJIA) and systemic lupus erythematosus (SLE). The pathophysiology involves:

  • Aberrant Immune Activation: Excessive activation and proliferation of macrophages and T-lymphocytes.

  • Cytokine Storm: Overproduction of cytokines similar to HLH, leading to systemic hyperinflammation.

  • Organ Damage: Due to cytokine-mediated damage and immune cell infiltration.

  Clinical Presentation:

  • Persistent high fever

  • Hepatosplenomegaly

  • Lymphadenopathy

  • Hemorrhagic manifestations (petechiae, mucosal bleeding)

  • Central nervous system involvement (seizures, confusion)

  Laboratory Findings:

  • Hyperferritinemia: Elevated ferritin levels (often >500 ng/mL, can be >10,000 ng/mL)

  • Cytopenias: Thrombocytopenia, leukopenia, anemia

  • Elevated liver enzymes: ALT, AST

  • Coagulopathy: Prolonged PT/PTT, low fibrinogen

  • Elevated triglycerides

  Diagnostic Criteria (sJIA-associated MAS, 2016 EULAR/ACR/PRINTO): To diagnose MAS in patients with sJIA, the following criteria are used:

  1. Fever ≥ 37.5°C

  2. Ferritin > 684 ng/mL and any two of the following:

     • Platelet count ≤ 181 x 10^9/L

     • Aspartate aminotransferase (AST) > 48 units/L

     • Triglycerides > 156 mg/dL

     • Fibrinogen ≤ 360 mg/dL

  Management:

  • High-dose corticosteroids: First-line treatment (e.g., methylprednisolone)

  • Immunosuppressive agents: Cyclosporine, anakinra (IL-1 receptor antagonist)

  • Biologic agents: Tocilizumab (IL-6 receptor antagonist), rituximab (anti-CD20)

Essential Points for Differentiating HLH and MAS

• Context of Occurrence:

  • HLH can be primary (genetic) or secondary (triggered by infections, malignancies, autoimmune diseases).

  • MAS occurs in the context of underlying rheumatic diseases like sJIA and SLE.

• Diagnostic Criteria:

  • HLH diagnosis requires meeting five out of eight criteria from the HLH-2004 guidelines.

  • MAS diagnosis in sJIA patients follows specific criteria focusing on ferritin levels and other laboratory findings.

• Management Strategies:

  • HLH treatment involves intensive immunosuppressive therapy and possibly hematopoietic stem cell transplantation.

  • MAS treatment primarily uses high-dose corticosteroids and other immunosuppressive therapies, with biologic agents as adjuncts.

• Common Features:

  • Both conditions involve hyperferritinemia, cytopenias, and hypercytokinemia.

  • Both conditions can present with fever, hepatosplenomegaly, and multi-organ dysfunction.
    

Conclusion

Hemophagocytic Lymphohistiocytosis (HLH) and Macrophage Activation Syndrome (MAS) are critical subsets of cytokine storm syndromes, characterized by hyperinflammation and multi-organ involvement. Prompt recognition and treatment are crucial to improving outcomes in these patients. Understanding the specific clinical and laboratory criteria for each syndrome, along with their respective management strategies, allows healthcare providers to make timely and effective therapeutic decisions.